TEVA PHARMACEUTICAL INDUSTRIES LTD

Key metrics

Financial performance

Over the last 9 fiscal years TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue declined from $21.90B to $17.26B, a compound annual decline rate of 2.6%. Net profit margin expanded from 1.5% to 8.2% over the same period - every figure below comes from the company's audited annual filings.

Key statistics

Latest filings

Browse the full filing history (2,473 filings)

Recent press releases

• TEV-‘749 utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that provides a controlled, steady, prolonged release of olanzapine.2026-05-21

  The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

• Fitch’s report highlights Teva’s sustained progress in strengthening financial flexibility and advancing its transition toward a higher-margin innovative and biosimilar portfolio. Fitch expects continued growth in innovative revenues, led by AUSTEDO® and AJOVY®; as well as contributions from recently launched products such as UZEDY® and upcoming launches, including olanzapine LAI, subject to regulatory approval. Fitch also expects Teva’s efficiency programs and portfolio shift to support its operating margin improvement and continued strong cash generation. Fitch further noted Teva’s ongoing balance sheet strengthening, supported by sustained cash flow generation, enhancing financial flexibility.2026-05-18

  Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

• “The latest data from the IMPACT-TD Registry underscores the profound, multidimensional impact of tardive dyskinesia on individuals, extending far beyond any single demographic. Despite its widespread impact, we are still confronted with meaningful diagnostic gaps, leaving many patients undiagnosed and untreated,” said Verena Ramirez Campos, MD-MBA, Vice President U.S. Medical Affairs and Global Innovative Strategy at Teva. “We are committed to grasping the complete human experience of TD, and working to help close those gaps and bring forth innovations that make a meaningful difference in the day-to-day lives of people living with TD.”2026-05-18

  Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Similar companies

The largest companies sharing TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC industry classification (pharmaceutical preparations).